Bleeding risk with multiple anti-thrombotics

In this large retrospective analysis of >82,000 Danish patients discharged after an episode of new atrial fibrillation, their risk of fatal or non-fatal bleeding was assessed according to post-hospital anti-thrombotics (ASA, clopidogrel, warfarin, or any combination). Using warfarin as the reference standard, risk of bleeding escalated with number of medications used, ranging from a hazard ratio of 0.93 for ASA monotherapy, to a hazard ratio of 3.7 for all 3 combined. The use of multiple anti-thrombotics significantly increases the risk of bleeding, so should be thoughtfully prescribed with that risk in mind (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment